Despite decades of investigation, stem cell therapies are still facing challenges around their commercialization. The stem cell therapy market has been struggling to achieve approvals and high price tags have made it difficult to generate sales for those that do reach commercialization. Moreover, it is a challenging task to introduce foreign living cells into a system as complex as the human body. [Read more…]
The company’s MEV universal delivery system has the potential to overcome biological barriers in the body and solve current drug delivery challenges.
Paris, April 3, 2023 – AGS Therapeutics, an early-stage biotech company pioneering micro-algae extracellular vesicles (MEV) as a new delivery system for innovative therapeutic treatments, today announced its initial internal research and development (R&D) pipeline. It is designed to showcase the potential of its MEVs as a new groundbreaking delivery system for bringing a wide range of payloads, including mRNA, siRNA, plasmid-DNA, antisense oligonucleotides (ASO), peptides, and proteins, to a variety of tissues and organs for treatment of a wide range of diseases. MEVs can overcome many of the challenges met by current delivery systems based on mammalian extracellular vesicles and on synthetic lipid nanoparticles. [Read more…]
Exosomes are produced and secreted out by nearly all living cells and have been found to occur in nearly every bodily fluid. They are found abundantly in the growth medium of many cultured cells, such as B lymphocytes, dendritic cells, cytotoxic T cells, intestinal epithelial cells, neurons, oligodendrocytes, platelets, mast cells and Schwann cells. [Read more…]
Collaboration with La Trobe University, The University of Queensland, Australian National University, Cytiva and SeerPharma Pty Ltd
19 January 2023, Melbourne, Australia – VivaZome Therapeutics Pty Ltd (“VivaZome”) is delighted to announce that it has been awarded an Australian Government Round 13 CRC-P grant of $3.0m in support of the project “Customised exosomes – the future of regenerative medicine”. [Read more…]
Naïve exosomes can be engineered to load drugs into their lumen using two different technologies: passive drug loading and active drug loading. These “drugs” can include RNAs, proteins, and nucleic acids, as well as other payloads. Today, a growing number of companies are using engineered exosomes for therapeutic purposes and studies by these companies have confirmed that exosomes can effectively serve as carrier vehicles for several types of bioactive molecules. Several exosome therapeutics have also entered into clinical testing. [Read more…]